Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 18/20 | 0.82 |
| ▸ | MEN1 | O00255 | 3/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.82 |
| ▸ | HBB | P68871 | 2/20 | 0.82 |
| ▸ | CASP1 | P29466 | 1/20 | 0.82 |
| ▸ | CASP7 | P55210 | 1/20 | 0.82 |
| ▸ | TP53 | P04637 | 2/20 | 0.79 |
| ▸ | GLA | P06280 | 2/20 | 0.79 |
| ▸ | HPGD | P15428 | 2/20 | 0.79 |
| ▸ | STAT6 | P42226 | 1/20 | 0.79 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.79 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.79 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.79 |
| ▸ | GMNN | O75496 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23358409 | 1.00 | TOP1 (0.82) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL28123033 | 0.99 | TOP1 (0.81) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL5723890 | 0.94 | TOP1 (0.81) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL18296582 | 0.93 | TOP1 (0.79) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL9749459 | 0.93 | TOP1 (0.81) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL8480542 | 0.93 | TOP1 (0.79) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL27463178 | 0.93 | TOP1 (0.79) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL29225713 | 0.91 | TOP1 (0.81) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL18296774 | 0.91 | TOP1 (0.77) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL7262395 | 0.91 | TOP1 (0.80) | TOP1MEN1KMT2ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022120490-A1 | CYTOCHROME P450 MONOOXYGENASES AND USES THEREOF | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-06-16 | — | — | WO | claimed |
| WO-2007095389-A2 | TREATMENT OF HYPERPROLIFERATIVE DISEASES WITH CAMPTOTHECINE N-OXIDE AND ANALOGS | NOVACEA, INC. (US) | 2007-08-23 | — | — | WO | claimed |
| CN-1159192-A | Substituted camptothecin derivatives and process for their preparation | PHARMACIA & UPJOHN SPA (IT) | 1997-09-10 | — | — | CN | claimed |
| EP-0777670-A1 | SUBSTITUTED CAMPTOTHECIN DERIVATIVES AND PROCESS FOR THEIR PREPARATION | PHARMACIA & UPJOHN S.p.A. (IT) | 1997-06-11 | — | — | EP | claimed |
| WO-1996037496-A1 | SUBSTITUTED CAMPTOTHECIN DERIVATIVES AND PROCESS FOR THEIR PREPARATION | PHARMACIA & UPJOHN S.P.A. (IT) | 1996-11-28 | — | — | WO | claimed |
| WO-1995028404-A1 | 7,11 DISUBSTITUTED CAMPTOTHECIN DERIVATIVES, FORMULATIONS CONTAINING SUCH DERIVATIVES AND THEIR USE | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1995-10-26 | — | — | WO | claimed |
| CN-120058720-A | Preparation and application of 7-alkyl camptothecine derivative containing hydroxylamine structure substitution | 杭州爱科瑞思生物医药有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-120058721-A | Preparation and application of 7-fluoroalkyl substituted camptothecine derivative | 杭州爱科瑞思生物医药有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-20240325553-A1 | CYTOSTATIC CONJUGATES WITH INTEGRIN LIGANDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-10-03 | — | — | US | disclosed |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | EDISON ONCOLOGY (US) | 2024-05-16 | — | — | US | disclosed |
| CN-118001423-A | Hydrophilic anti-Nectin-4 antibody coupled drug as well as preparation method and application thereof | 杭州爱科瑞思生物医药有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-20240084272-A1 | CYTOCHROME P450 MONOOXYGENASES AND USES THEREOF | UNIV BRITISH COLUMBIA (CA) | 2024-03-14 | — | — | US | disclosed |
| US-20240042045-A1 | NANOPARTICLES CONTAINING MULTIPLE CLEAVABLE PRODUGS FOR CANCER THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-02-08 | — | — | US | disclosed |
| WO-2002036073-A2 | RECEPTOR ANTAGONIST-LIPID CONJUGATES AND DELIVERY VEHICLES CONTAINING SAME | SMITHKLINE BEECHAM CORPORATION (US) | 2002-05-10 | — | — | WO | disclosed |
| US-5856333-A | ANTITUMOR AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 1999-01-05 | — | — | US | disclosed |
| CN-1159192-A | Substituted camptothecin derivatives and process for their preparation | PHARMACIA & UPJOHN SPA (IT) | 1997-09-10 | — | — | CN | disclosed |
| EP-0777670-A1 | SUBSTITUTED CAMPTOTHECIN DERIVATIVES AND PROCESS FOR THEIR PREPARATION | PHARMACIA & UPJOHN S.p.A. (IT) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996037496-A1 | SUBSTITUTED CAMPTOTHECIN DERIVATIVES AND PROCESS FOR THEIR PREPARATION | PHARMACIA & UPJOHN S.P.A. (IT) | 1996-11-28 | — | — | WO | disclosed |
| WO-1995028404-A1 | 7,11 DISUBSTITUTED CAMPTOTHECIN DERIVATIVES, FORMULATIONS CONTAINING SUCH DERIVATIVES AND THEIR USE | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1995-10-26 | — | — | WO | disclosed |
| WO-1995028404-A1 | 7,11 DISUBSTITUTED CAMPTOTHECIN DERIVATIVES, FORMULATIONS CONTAINING SUCH DERIVATIVES AND THEIR USE | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1995-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325553-A1 | CYTOSTATIC CONJUGATES WITH INTEGRIN LIGANDS | ITGAV, ITGB3, ITGAL | TOP1 1856/4885MEN1 2248/4885KMT2A 3943/4885 |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | TOP2A, TOP2B, TOP1 | TOP1 3/4885MEN1 601/4885KMT2A 1727/4885 |
| US-20240084272-A1 | CYTOCHROME P450 MONOOXYGENASES AND USES THEREOF | CYP3A43, CYP11B2, CYP11B1 | TOP1 367/4885MEN1 2868/4885KMT2A 3443/4885 |
| US-20240042045-A1 | NANOPARTICLES CONTAINING MULTIPLE CLEAVABLE PRODUGS FOR CANCER THERAPY | LDLR, LRP6, LIPG | TOP1 1044/4885MEN1 3166/4885KMT2A 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.